ADPT (Adaptive Biotechnologies) Long-Term Debt: $0.0 Mil (As of Mar. 2026)


ADPT Adaptive Biotechnologies Corp ADPT
68 GF Score
Price $21.50
GF Value $10.05
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Adaptive Biotechnologies Long-Term Debt?

Adaptive Biotechnologies ADPT 68 Long-Term Debt is $0.0 Mil as of Mar. 2026. GuruFocus rates ADPT with a GF Score™ of 68/100 and a GF Value™ of $10.05 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Adaptive Biotechnologies's Long-Term Debt for the quarter that ended in Mar. 2026 was $0.0 Mil.

Adaptive Biotechnologies  (NAS:ADPT) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Adaptive Biotechnologies Long-Term Debt Related Terms

Adaptive Biotechnologies Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Adaptive Biotechnologies's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptive Biotechnologies Long-Term Debt Chart

Adaptive Biotechnologies Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Adaptive Biotechnologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ADPT
68GF Score
Adaptive Biotechnologies Corp ADPT
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.0 Mil mean?
Adaptive Biotechnologies (ADPT) has a Long-Term Debt of $0.0 Mil as of Mar. 2026.
Is Adaptive Biotechnologies' Long-Term Debt too high?
Adaptive Biotechnologies' current Long-Term Debt is $0.0 Mil. Overall, Adaptive Biotechnologies has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adaptive Biotechnologies' Long-Term Debt compare to GRAL and WGS?
Adaptive Biotechnologies' Long-Term Debt of $0.0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Diagnostics & Research company?
A good Long-Term Debt depends on the Medical Diagnostics & Research industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Adaptive Biotechnologies's current Long-Term Debt is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptive Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, Adaptive Biotechnologies (ADPT) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.05, compared to a current price of $21.50 — trading 113.9% above its estimated fair value. The current Long-Term Debt is $0.0 Mil. Adaptive Biotechnologies' overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Adaptive Biotechnologies (ADPT), the current Long-Term Debt is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adaptive Biotechnologies (ADPT) Overvalued in 2026?

Based on GuruFocus' analysis, Adaptive Biotechnologies stock appears to be overvalued. The current stock price of $21.50 is trading 113.9% above its estimated GF Value™ of $10.05. GuruFocus considers Adaptive Biotechnologies to be Significantly Overvalued.

Key valuation signals for ADPT:

  • Long-Term Debt: $0.0 Mil
  • GF Value™: $10.05 vs. price of $21.50 (113.9% above fair value)
  • GF Score™: 68/100 with 5 warning signs

No single metric tells the full story. See the ADPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adaptive Biotechnologies Business Description

Other Exchanges 1HM:Germany
Address 1165 Eastlake Avenue East, Seattle, WA, USA, 98109
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
68GF Score

Get the complete analysis for ADPT

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.50
Price
$10.05
GF Value